Novel tuberculosis vaccine shows promising immunogenicity and safety profile
Vaccine is produced by SSI and contains Intercell's adjuvant IC31
The new H1 vaccine from SSI is a recombinant subunit vaccine based on two important TB antigens resulting from SSI's research pipeline combined with Intercell's proprietary adjuvant IC31(TM). The phase I clinical trial was performed at the Department of Infectious Diseases (headed by Prof. Jaap van Dissel) at Leiden University Medical Center in the Netherlands and was supported by the European Union-funded program "TB-VAC".
H1 is a TB vaccine antigen in which two immuno dominant TB antigens (Ag85B and ESAT6) are fused together by recombinant technology and produced as a poly-protein. IC31TM is an adjuvant inducing both T-cell and B-cell responses with a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens, no conjugation is required.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.